Agreement

RNS Number:2664R
Profile Therapeutics PLC
24 October 2003


Immediate Release                                       07:00am 24 October 2003


                            Profile Therapeutics plc

                 Profile Signs Inhaler Agreement with Schering


Profile Therapeutics plc ("Profile"), which develops and commercialises
specialist inhaled therapies, is delighted to announce the signing of an
agreement with Schering Health Care Ltd. ("Schering"), a division of Schering
AG.


Under the terms of the agreement, Profile will supply Schering with Prodose
intelligent inhalers for use with Schering's recently approved medicine for
Primary Pulmonary Hypertension, Ventavis(R)?. Profile will also provide a patient
support programme including training services, a support helpline and
consumables for the Prodose. Profile will receive payments from Schering for
each Prodose patient.


Primary Pulmonary Hypertension ("PPH") is a rare lung disorder in which the
blood pressure in the pulmonary artery rises far above normal levels for no
apparent reason(1). There are around 200 patients in the UK and approximately
2,000 across Europe. Profile is continuing to discuss with Schering how it can
support Ventavis(R) in other European markets.


Commenting on today's announcement, John Lisle, Chief Executive of Profile,
said:


"This agreement is great news for patients as it gives them a state-of-the-art
delivery system to help improve the effectiveness of their treatment and the
quality of life. It is also an important step for Profile as we are now have two
medicines being delivered through our Adaptive Aerosol Delivery systems."


                                    - ENDS -


(1) Primary Pulmonary Hypertension: division of lung diseases and office of
prevention, education and control. US department of Health and Human Services.
Public Health Service. National Institutes of Health. National Heart, Lung and
Blood Institute. NIH Publication No. 96-3291, Revised November 1996.


For further information, please contact:

Profile Therapeutics
John Lisle, Chief Executive Officer                          Tel: [phone]
Simon McGuire, Sales & Marketing Director


Buchanan Communications                                      Tel: [phone]
Tim Anderson
James Strong



Notes to Editors:


Profile Therapeutics plc develops and commercialises specialist inhaled
therapies to improve the treatment of respiratory patients. Profile's core
patient groups are the young, the elderly and individuals with severe
respiratory impairment. The diseases targeted by Profile include: cystic
fibrosis, primary pulmonary hypertension, asthma, emphysema, chronic bronchitis,
sleep disorders and Chronic Obstructive Pulmonary Disease ("COPD").


Profile has developed proprietary innovative delivery systems using its
"intelligent inhaler" technology known as Adaptive Aerosol delivery or AAD(R)?.
These systems automatically respond to individual patients' breathing patterns
to deliver a precise dose and have been shown under long-term clinical trials to
significantly enhance patient compliance to therapy.


Profile's first drug PromixinTM, an inhaled antibiotic for cystic fibrosis
patients, was launched in the UK in March 2003. Schering's Ventavis(R) is the
second medicine to be delivered using the Prodose and Profile has also formed a
joint venture with Breath Ltd to develop a range of respiratory medicines for
the US market for delivery via Profile's intelligent inhalers.






                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
AGREAPEDAFADFFE